مباشر
FierceBiotechLilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’Endpoints NewsBiopharma’s 2025 industry pay report; Parabilis sets industry record IPO; and moreClinical OMICsLong-Read DNA Test Could Replace 15 Existing Tests for Rare DiseasesClinical OMICsMaternal Blood Test Allows Comprehensive Genetic Fetal ScreeningEndpoints NewsMerck brings Welireg-Keytruda combo to treat kidney cancerFDA News ReleasesFDA Clears First Over-the-Counter Continuous Glucose Monitor for ChildrenClinical OMICsFrom Multi-Omics to Digital Twins: A Data-Driven Future for Precision MedicineClinical OMICsAge-Related Mutations in Brain Immune Cells Linked to Alzheimer’s InflammationClinical OMICsPaper Mills and the Fight Against Scientific FraudClinical OMICsNanowire Device Captures EVs for Targeted Cancer Liquid BiopsiesCellComplete biosynthesis of the anticancer cephalotaxinone and homoerythratineEndpoints NewsAmgen and the FDA want two different outcomes for Tavneos. What will patients do?
Endpoints News ٢١ يناير ٢٠٢٦

#JPM26: Regeneron, Lilly, Summit on rivals crowding into same targets

#JPM26: Regeneron, Lilly, Summit on rivals crowding into same targets

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.